UNSPSC 51283601: Rifampicin or rifampin

This classification denotes a rna polymerase inhibitor and antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(n-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione 21-acetate but generally known as rifampicin, which bears US NIH Compound Identifier 5381226.

UNSPSC 51283601 Rifampicin or rifampin is a Commodity code that shows minimal direct alignment with recent state and local procurement activity. The three substantive opportunities posted under or near this code—a Seminole County naloxone and drug deactivation systems IFB, a Texas HHS Therapeutic Pharmacy Initiative RFI, and a Minnesota MMCAP generic pharmaceuticals and OTC products RFP—involve procurement of broad pharmaceutical and medical supply categories rather than rifampicin-specific acquisitions. The City of Tampa's medical and first aid supplies IFB for the Fire Department Rescue Division centers on respiratory equipment, cardiac monitoring supplies, and emergency consumables with no reference to tuberculosis or mycobacterial treatments. The mismatch suggests this commodity code either sees limited state and local demand for rifampicin as a standalone pharmaceutical line item or that jurisdictions tag broader pharmaceutical procurements with higher-level taxonomy codes rather than specific drug commodities.

Recent activity appears concentrated in cooperative purchasing vehicles and health agency channels. The Minnesota Department of Administration's MMCAP RFP, posted January 20, 2026 with a March 26, 2026 response date, is the most substantial signal—a multistate cooperative purchasing agreement for generic pharmaceuticals with NDC-specific requirements, cGMP and DSCSA compliance mandates, and mandatory distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Texas HHS RFI issued April 3, 2026 signals exploratory interest in direct-to-manufacturer pharmacy models but remains in market-intelligence phase. Seminole County's July 26, 2023 IFB deadline has passed. Pursuit under this code requires tracking MMCAP amendments or successor cooperative agreements and monitoring state health and human services RFPs that itemize tuberculosis and atypical mycobacterial treatments, which do not yet appear in the current opportunities block.